INmune Bio Inc. Announces Third Quarter 2026 Results and Provides Business Update
Globe Newswire•05/11/2026•16:00 ET
0
Key Highlights
- ➤Ebstrocel MAA submission to UK MHRA targeted for early February 2027
- ➤Potential UK approval expected in mid-2027, subject to MHRA review
- ➤Q3 net loss $4.7 million, down from $6.5 million year over year
- ➤Cash $16.3 million; company expects funding through third quarter of 2027
- ➤October stock and warrant offering raised $4.5 million gross proceeds
Expert Statements
David Moss, Chief Executive Officer of INmune Bio
“INmune Bio is approaching regulatory milestones for Ebstrocel that can establish our first commercial product”
David Moss, Chief Executive Officer of INmune Bio
“We have made substantial progress in manufacturing, regulatory preparation and international patient access, giving us increased confidence in our ability to bring Ebstrocel to patients suffering from recessive dystrophic epidermolysis bullosa (RDEB).”
David Moss, Chief Executive Officer of INmune Bio
“We believe the strength of our clinical data, our alignment with the MHRA and our progress in manufacturing provide a compelling foundation for approval.”
David Moss, Chief Executive Officer of INmune Bio
“Importantly, our agreement with Uniphar builds a framework that could provide access to patients in additional international markets ahead of broader commercial launches.”
David Moss, Chief Executive Officer of INmune Bio
“We are focused on executing our regulatory strategy, building commercial readiness and allocating capital to the milestones that we believe will create the greatest value for patients and shareholders.”
Company to Host Conference Call on November 5, 2026, at 4:30pm ET
BOCA RATON, Fla., Nov. 05, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announces its financial results for the quarter ended September 30, 2026, and provides a business update.
Get started
Create a free account to read the full story.